22 min listen
The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates
The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates
ratings:
Length:
74 minutes
Released:
Apr 3, 2024
Format:
Podcast episode
Description
Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayB7H3ADCs23).
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayB7H3ADCs23).
Released:
Apr 3, 2024
Format:
Podcast episode
Titles in the series (100)
Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle: Dr Tom Lynch comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. by Oncology Today with Dr Neil Love